Revive Therapeutics Announces Positive Results of its Novel Cannabinoid Delivery Technology

Biotech Investing

Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) has announced positive initial results from its research product with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.

As quoted in the press release:

The research project evaluated tannin-chitosan (TNN-CHT) based hydrogel formulations in combination with synthetic cannabidiol (CBD) in an anti-inflammatory preclinical model. Initial results successfully demonstrated a stable formulation of the TNN-CHT composites and synthetic CBD (TNN-CHT/CBD). more at